Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 13/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CCND1 | P24385 | 2/20 | 0.47 |
| ▸ | ABL2 | P42684 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | CDK7 | P50613 | 2/20 | 0.47 |
| ▸ | CCNH | P51946 | 2/20 | 0.47 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098805 | 0.85 | CDK9 (0.71) | CDK9CCNT1LMNAMAP4K4CDK1 | |
| SCHEMBL4103487 | 0.84 | CDK9 (0.72) | CDK9CCNT1LMNAMAP4K4CDK1 | |
| SCHEMBL4113919 | 0.81 | CDK9 (0.60) | CDK9CCNT1LMNA | |
| SCHEMBL4103526 | 0.77 | CDK9 (0.68) | CDK9CCNT1LMNAMAP4K4CDK1 | |
| SCHEMBL4114658 | 0.77 | USP2 (0.62) | CDK9CCNT1LMNAMAP4K4CDK1 | |
| SCHEMBL4429854 | 0.73 | CDK9 (0.72) | CDK9CCNT1LMNAMAP4K4CDK1 | |
| SCHEMBL4101973 | 0.71 | CDK9 (0.82) | CDK9CCNT1LMNAMAP4K4CDK1 | |
| SCHEMBL4103796 | 0.71 | CDK9 (0.72) | CDK9CCNT1LMNAMAP4K4CDK1 | |
| SCHEMBL4109347 | 0.71 | CDK9 (0.74) | CDK9CCNT1LMNAMAP4K4CDK1 | |
| SCHEMBL4111374 | 0.70 | CDK9 (0.77) | CDK9CCNT1LMNAMAP4K4CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678147-B1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-08-08 | — | — | EP | claimed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | claimed |
| EP-1678147-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC Biotech AG (DE) | 2006-07-12 | — | — | EP | claimed |
| WO-2005026129-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC BIOTECH AG (DE) | 2005-03-24 | — | — | WO | claimed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-1901747-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | Ingenium Pharmaceuticals AG (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006125616-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS AG (DE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221581-A1 | Methods of treating pain | CDK5, CAMKK2, CDK3 | CDK9 97/4885CCNT1 81/4885LMNA 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.